These are two cheap stocks in an overvalued market.
News & Analysis: GlaxoSmithKline
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.
These two high-dividend stocks might be great additions to your portfolio.
GSK earnings call for the period ending March 31, 2021.
GlaxoSmithKline presents a great opportunity for investors this year.
An activist investor is reportedly building a significant position in the drugmaker.
Despite the pandemic, these companies are still profitable and reporting strong results.
GSK earnings call for the period ending December 31, 2020.
Dr. Angela Rasmussen explains what investors should know about an under-the-radar coronavirus vaccine developer.
The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.